Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

Publikation: Bidrag til tidsskriftReviewForskningpeer review

Harvard

Bartenschlager, R, Baumert, TF, Bukh, J, Houghton, M, Lemon, SM, Lindenbach, BD, Lohmann, V, Moradpour, D, Pietschmann, T, Rice, CM, Thimme, R & Wakita, T 2018, 'Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies', Virus Genes, bind 248, s. 53-62. https://doi.org/10.1016/j.virusres.2018.02.016

APA

Bartenschlager, R., Baumert, T. F., Bukh, J., Houghton, M., Lemon, S. M., Lindenbach, B. D., Lohmann, V., Moradpour, D., Pietschmann, T., Rice, C. M., Thimme, R., & Wakita, T. (2018). Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Genes, 248, 53-62. https://doi.org/10.1016/j.virusres.2018.02.016

CBE

Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T. 2018. Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Genes. 248:53-62. https://doi.org/10.1016/j.virusres.2018.02.016

MLA

Vancouver

Author

Bartenschlager, Ralf ; Baumert, Thomas F ; Bukh, Jens ; Houghton, Michael ; Lemon, Stanley M ; Lindenbach, Brett D ; Lohmann, Volker ; Moradpour, Darius ; Pietschmann, Thomas ; Rice, Charles M ; Thimme, Robert ; Wakita, Takaji. / Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy : Considerations for scientists and funding agencies. I: Virus Genes. 2018 ; Bind 248. s. 53-62.

Bibtex

@article{b368a5639f4c457fb556878da7cab25d,
title = "Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies",
abstract = "The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider HCV amenable to eradication, and continued research on the virus of little remaining medical relevance. However, given 400,000 HCV-related deaths annually important challenges remain, including identifying those who are infected, providing access to treatment and reducing its costs. Moreover, HCV infection rarely induces sterilizing immunity, and those who have been cured with DAAs remain at risk for reinfection. Thus, it is very unlikely that global eradication and elimination of the cancer risk associated with HCV infection can be achieved without a vaccine, yet research in that direction receives little attention. Further, over the past two decades HCV research has spearheaded numerous fundamental discoveries in the fields of molecular and cell biology, immunology and microbiology. It will continue to do so, given the unique opportunities afforded by the reagents and knowledge base that have been generated in the development and clinical application of DAAs. Considering these critical challenges and new opportunities, we conclude that funding for HCV research must be sustained.",
keywords = "Journal Article, Review",
author = "Ralf Bartenschlager and Baumert, {Thomas F} and Jens Bukh and Michael Houghton and Lemon, {Stanley M} and Lindenbach, {Brett D} and Volker Lohmann and Darius Moradpour and Thomas Pietschmann and Rice, {Charles M} and Robert Thimme and Takaji Wakita",
note = "Copyright {\textcopyright} 2018 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2018",
month = mar,
doi = "10.1016/j.virusres.2018.02.016",
language = "English",
volume = "248",
pages = "53--62",
journal = "Virus Genes",
issn = "0920-8569",
publisher = "Springer New York LLC",

}

RIS

TY - JOUR

T1 - Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy

T2 - Considerations for scientists and funding agencies

AU - Bartenschlager, Ralf

AU - Baumert, Thomas F

AU - Bukh, Jens

AU - Houghton, Michael

AU - Lemon, Stanley M

AU - Lindenbach, Brett D

AU - Lohmann, Volker

AU - Moradpour, Darius

AU - Pietschmann, Thomas

AU - Rice, Charles M

AU - Thimme, Robert

AU - Wakita, Takaji

N1 - Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider HCV amenable to eradication, and continued research on the virus of little remaining medical relevance. However, given 400,000 HCV-related deaths annually important challenges remain, including identifying those who are infected, providing access to treatment and reducing its costs. Moreover, HCV infection rarely induces sterilizing immunity, and those who have been cured with DAAs remain at risk for reinfection. Thus, it is very unlikely that global eradication and elimination of the cancer risk associated with HCV infection can be achieved without a vaccine, yet research in that direction receives little attention. Further, over the past two decades HCV research has spearheaded numerous fundamental discoveries in the fields of molecular and cell biology, immunology and microbiology. It will continue to do so, given the unique opportunities afforded by the reagents and knowledge base that have been generated in the development and clinical application of DAAs. Considering these critical challenges and new opportunities, we conclude that funding for HCV research must be sustained.

AB - The development and clinical implementation of direct-acting antivirals (DAAs) has revolutionized the treatment of chronic hepatitis C. Infection with any hepatitis C virus (HCV) genotype can now be eliminated in more than 95% of patients with short courses of all-oral, well-tolerated drugs, even in those with advanced liver disease and liver transplant recipients. DAAs have proven so successful that some now consider HCV amenable to eradication, and continued research on the virus of little remaining medical relevance. However, given 400,000 HCV-related deaths annually important challenges remain, including identifying those who are infected, providing access to treatment and reducing its costs. Moreover, HCV infection rarely induces sterilizing immunity, and those who have been cured with DAAs remain at risk for reinfection. Thus, it is very unlikely that global eradication and elimination of the cancer risk associated with HCV infection can be achieved without a vaccine, yet research in that direction receives little attention. Further, over the past two decades HCV research has spearheaded numerous fundamental discoveries in the fields of molecular and cell biology, immunology and microbiology. It will continue to do so, given the unique opportunities afforded by the reagents and knowledge base that have been generated in the development and clinical application of DAAs. Considering these critical challenges and new opportunities, we conclude that funding for HCV research must be sustained.

KW - Journal Article

KW - Review

U2 - 10.1016/j.virusres.2018.02.016

DO - 10.1016/j.virusres.2018.02.016

M3 - Review

C2 - 29477639

VL - 248

SP - 53

EP - 62

JO - Virus Genes

JF - Virus Genes

SN - 0920-8569

ER -

ID: 53366540